Search

Your search keyword '"Mach, François' showing total 2,293 results

Search Constraints

Start Over You searched for: Author "Mach, François Remove constraint Author: "Mach, François
2,293 results on '"Mach, François'

Search Results

1. Data sharing: A new editorial initiative of the International Committee of Medical Journal Editors. Implications for the Editors´ Network

2. A systematic review and meta-analysis of differences between men and women in short-term outcomes following coronary artery bypass graft surgery

3. Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes

5. Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial

7. Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial

10. Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study

11. Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table

12. Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study

15. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

17. Recruiting medical students as first responders in the immediate aftermath of the COVID-19 pandemic: Prospective follow-up study (Preprint)

18. Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction

19. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT

22. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial

23. Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial

24. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

26. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

27. Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland

30. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

31. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study–Rationale and design of the PACMAN-AMI trial

35. Body temperature, systemic inflammation and risk of adverse events in patients with acute coronary syndromes.

37. Impact of the 2021 European Society for Cardiology prevention guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease

39. Association Between Patient Sex and Familial Hypercholesterolemia and Long-Term Cardiovascular Risk Factor Management 5 Years After Acute Coronary Syndrome.

41. Impact of the 2021 European Society for Cardiology prevention guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease

44. Higher 1‐year mortality on rest days in patients with acute coronary syndromes and decompensated heart failure—A SPUM‐ACS sub‐study

45. Window of opportunity for developing effective medical intervention for calcific aortic valve disease.

49. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

50. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Catalog

Books, media, physical & digital resources